Phage therapy against multi-resistant bacteria
DOI:
https://doi.org/10.35381/s.v.v8i1.3919Keywords:
Anti-bacterial agents, antifungal agents, therapeutic use, (Source: DeCS)Abstract
Objective: To analyze phage therapy against multi-resistant bacterias. Method: Descriptive documentary. Conclusion: Phage therapy offers real hope for the treatment of bacterial infections, especially those caused by multidrug-resistant microorganisms. However, further research, clinical trials and adequate regulation are needed for its development and wider adoption in clinical practice.
Downloads
References
Hatfull GF, Dedrick RM, Schooley RT. Phage Therapy for Antibiotic-Resistant Bacterial Infections. Annu Rev Med. 2022;73:197-211. https://doi.org/10.1146/annurev-med-080219-122208
Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: From biological mechanisms to future directions. Cell. 2023;186(1):17-31. https://doi.org/10.1016/j.cell.2022.11.017
Suh GA, Lodise TP, Tamma PD, et al. Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrob Agents Chemother. 2022;66(3):e0207121. https://doi.org/10.1128/AAC.02071-21
Xu HM, Xu WM, Zhang L. Current Status of Phage Therapy against Infectious Diseases and Potential Application beyond Infectious Diseases. Int J Clin Pract. 2022;2022:4913146. https://doi.org/10.1155/2022/4913146
Luong T, Salabarria AC, Roach DR. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?. Clin Ther. 2020;42(9):1659-1680. https://doi.org/10.1016/j.clinthera.2020.07.014
Tagliaferri TL, Jansen M, Horz HP. Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy. Front Cell Infect Microbiol. 2019;9:22. https://doi.org/10.3389/fcimb.2019.00022
Patey O, McCallin S, Mazure H, Liddle M, Smithyman A, Dublanchet A. Clinical Indications and Compassionate Use of Phage Therapy: Personal Experience and Literature Review with a Focus on Osteoarticular Infections. Viruses. 2018;11(1):18. https://doi.org/10.3390/v11010018
Onallah H, Hazan R, Nir-Paz R, et al. Refractory Pseudomonas aeruginosa infections treated with phage PASA16: A compassionate use case series. Med. 2023;4(9):600-611.e4. https://doi.org/10.1016/j.medj.2023.07.002
Torres-Barceló C, Hochberg ME. Evolutionary Rationale for Phages as Complements of Antibiotics. Trends Microbiol. 2016;24(4):249-256. https://doi.org/10.1016/j.tim.2015.12.011
Royer S, Morais AP, da Fonseca Batistão DW. Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts. Arch Microbiol. 2021;203(4):1271-1279. https://doi.org/10.1007/s00203-020-02167-5
Ferry T, Kolenda C, Briot T, et al. Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection. Viruses. 2021;13(12):2414. https://doi.org/10.3390/v13122414
Patil A, Banerji R, Kanojiya P, Koratkar S, Saroj S. Bacteriophages for ESKAPE: role in pathogenicity and measures of control. Expert Rev Anti Infect Ther. 2021;19(7):845-865. https://doi.org/10.1080/14787210.2021.1858800
Mohan Raj JR, Karunasagar I. Phages amid antimicrobial resistance. Crit Rev Microbiol. 2019;45(5-6):701-711. https://doi.org/10.1080/1040841X.2019.1691973
Lenneman BR, Fernbach J, Loessner MJ, Lu TK, Kilcher S. Enhancing phage therapy through synthetic biology and genome engineering. Curr Opin Biotechnol. 2021;68:151-159. https://doi.org/10.1016/j.copbio.2020.11.003
Valério N, Oliveira C, Jesus V, et al. Effects of single and combined use of bacteriophages and antibiotics to inactivate Escherichia coli. Virus Res. 2017;240:8-17. https://doi.org/10.1016/j.virusres.2017.07.015
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Mario David Pinta-Riofrio, Paola Monserrath Jiménez-Espinosa, Melany Alexandra Suárez-Jurado, Washington Paúl Culqui-Molina
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
